

RESEARCH ARTICLE

Open Access



# Active DNA end processing in micronuclei of ovarian cancer cells

Zizhi Tang<sup>1†</sup>, Juan Yang<sup>2†</sup>, Xin Wang<sup>1†</sup>, Ming Zeng<sup>1</sup>, Jing Wang<sup>3</sup>, Ao Wang<sup>2</sup>, Mingcai Zhao<sup>3</sup>, Liandi Guo<sup>4</sup>, Cong Liu<sup>2\*</sup>, Dehua Li<sup>2\*</sup> and Jie Chen<sup>2\*</sup>

## Abstract

**Background:** Ovarian cancer is one of the most deadly gynecological malignancies and inclined to recurrence and drug resistance. Previous studies showed that the tumorigenesis of ovarian cancers and their major histotypes are associated with genomic instability caused by defined sets of pathogenic mutations. In contrast, the mechanism that influences the development of drug resistance and disease recurrence is not well elucidated. Solid tumors are prone to chromosomal instability (CIN) and micronuclei formation (MN). Although MN is traditionally regarded as the outcome of genomic instability, recent investigation on its origin and final consequences reveal that the abnormal DNA metabolism in MN is a driver force for some types of catastrophic genomic rearrangements, accelerating dramatic genetic variation of cancer cells.

**Methods:** We used Indirect Immunofluorescent staining to visualize micronuclei and activation of DNA repair factors in ovarian cancer cell lines and biopsies.

**Results:** We show that ovarian cancer cells are disposed to form micronuclei upon genotoxic insults. Double strand DNA breaks (DSBs)-triggered insurgence of micronuclei is associated with unrepaired chromosomes passing through mitosis. According to their morphology and DNA staining, micronuclei compartments are divided into early and late stages that can be further characterized by differential staining of  $\gamma$ H2AX and 53BP1. We also show that MN compartments do not halt controlled DNA metabolism as sequestered nuclear repair factors are enriched at DNA breaks in MN compartments and efficiently process DNA ends to generate single-stranded DNA (ssDNA) structures. Interestingly, unknown factors are required for DNA end processing in MN in addition to the nuclear resection machinery. Finally, these hallmarks of micronuclei evolution depicted in cell culture were recapitulated in different stages of ovarian cancer biopsies.

**Conclusions:** In aggregate, our findings demonstrate that ovarian cancer cells are inclined to form micronuclei that undergo robust DNA metabolism and generate ssDNA structures, potentially destabilizing genomic structures and triggering genetic variation.

**Keywords:** Micronucleus, DNA damage, Ovarian cancer, ssDNA

## Background

Ovarian cancer is an aggressive gynecological malignancy with approximately 30% of overall 5-year survival rate, seriously threatening women's health. Epithelial ovarian cancer (EOC) accounts for the majority of ovarian malignancies and for 90% of advanced-stage disease and mortality. Although cytoreductive surgery combined

with chemotherapy takes effect in initial treatment of EOC, current therapy is very limited due to the asymptomatic nature of the early stages and about 60% patients become resistant to chemotherapy [1]. Thus, EOC has both a poor prognosis and a high fatality rate.

A plethora of report suggests that loss of genome stability contributes to the tumorigenesis of EOC [2]. Major histotypes of EOC associate with genetic alterations and genomic instability: high-grade serous ovarian cancer (HGSC) present high-penetration of *TP53* and *BRCA1/BRCA2* mutations while other types of OC

\* Correspondence: [congliu@scu.edu.cn](mailto:congliu@scu.edu.cn); [562372162@qq.com](mailto:562372162@qq.com); [cjzb@sina.com](mailto:cjzb@sina.com)

<sup>†</sup>Equal contributors

<sup>2</sup>Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu 610041, People's Republic of China  
Full list of author information is available at the end of the article



(clear cell and endometrioid cancer) harbor detrimental *ARID1A* mutation [3]. As pathogenic *BRCA1/BRCA2* mutations are highly mutagenic, causing large amount of SNV, copy number variation and structural variations and destabilizing the genome, a significant proportion of ovarian cancer display genomic and chromosomal instability attributed to DNA repair deficiencies. Partially due to the CIN caused by these pro-cancerous mutations, the post-therapy somatic genome of EOC is under quick evolution, displaying spatial and temporal heterogeneity in terms of genetic composition [4–6]. The heterogeneity in ovarian cancer tissue results in branched evolution that contributes to the arousal of drug resistance [7, 8].

The CIN of ovarian cancer is caused by defective DNA damage responses (DDR). DDR is activated upon genotoxic challenges to arrest cell-cycle and DNA replication, and triggers repair pathway to eliminate DNA lesions and preserve genome stability [9, 10]. The phosphorylation of H2AX on its Ser139, or  $\gamma$ H2AX, is triggered in the very early phase of DNA damage and can form damage-induced foci in the chromatin regions of damaged DNA [11].  $\gamma$ H2AX sets up a platform by which damage recognition factors and repair molecules including MDC1, TopBP1, RAD9-RAD1-HUS1, MRE11, RAD50, NBS1 and TP53, are recruited to execute DNA repair [9, 12]. Repair factors like BRCA1 and 53BP1 regulate DSB repair by balancing the pathway choice between non-homologous end joining (NHEJ) and homologous recombination (HR) [13]. The concordant action of these proteins play crucial roles in controlling the DNA end resection at early stage of DSB repair, generating appropriate amount of ssDNA that is required for HR. Insufficient processing of DNA end results in decreased HR while excessive or prolonged presence of aberrant ssDNA structures are potentially toxic to cells ([14] and unpublished data). Genetic impairment of these signaling mechanism or challenging of the cancer cells by chemo- or radiotherapy causes radical mutagenic processes and confers quick evolution of cancer genomes.

In addition to genetic aberrance caused by impaired DDR function in the nuclear compartment, recent study also suggest that micronucleus, DNA fragments disintegrated from daughter nuclei during preceding mitosis, plays important roles in genetic evolution of solid cancer. To date, most solid tumors and pre-cancerous lesions are shown to display elevated MN frequency due to inherent CIN [15]. Traditionally, micronuclei is viewed as the outcome of unrepaired DNA breaks and can be induced with genotoxic agents, such as chemical reagents or irradiation [16]. The level of MN constitutes a biomarker for chromosomal instability (CIN) [17, 18], or to predict sensitivity and outcome of radiotherapy [19, 20]. However, recent progress in high-resolution microscope

and genomic sequencing suggest that MN has improperly controlled DNA metabolism with truncated DDR signaling, which can trigger massive genomic rearrangements and drive quick evolution of cancer cells via genetic variation [21].

Despite these progress in understanding of the roles of micronuclei in genomic stability, aspects of DNA metabolism within MN compartments, such as processing of DNA ends and re-integration of micronuclei DNA back to the genome, is poorly characterized. In this work, we investigated the DNA metabolism of MN in genotoxic challenged ovarian cancer cells. We characterized the recruitment of DDR factors in IR-induced micronuclei, and show that damage signaling including the chromatin recruitment of  $\gamma$ H2AX, 53BP1 and DNA end processing is still active in micronuclei, which drives the evolution of micronuclei from early to late stages. Interestingly, micronuclei display different DDR patterns from main nuclei compartments in terms of DSB-recruitment of repair factors and employing of DNA end processing enzymes. Furthermore, hallmarks of DDR signals were demonstrated in off-nuclear compartments of clinically derived ovarian cancer biopsies. Taken together, our findings reveal the active DNA metabolism in micronuclei, generating intermediate DNA structures that potentially induce genomic rearrangements and drive evolution of cancer cells.

## Methods

### Cell culture

Ovarian cancer cell lines (OVCAR-8 and SKOV-3) purchased from ATCC were maintained in DMEM (GIBCO) supplemented with 10% Fetal Bovine Serum (FBS, Hyclone) and 100 U/ml Penicillin and 100 mg/ml streptomycin (GIBCO). Enzymatic digestion (Trypsin, GIBCO, 25200–056) was used for cell passage. All cells were propagated at 37 °C in 5% CO<sub>2</sub> incubator. Primary ovarian cancer cells were isolated from fresh tissue blocks by enzymatic digestion (Collagenase A, Roche, 10,103,578,001; Trypsin, GIBCO, 25200–056) for 2 h with occasional vortex. Isolated single cells were dispersed in RPMI-1640/10% FBS and grown in media supplemented with 10 mg/ml Metrigel (BD, 356234). After 48 h, experiments were performed when 70% of cells were attached.

### Sample collections from patient

Normal or ovarian cancer tissue samples were collected from West China Second University Hospital, Sichuan University. All performance of sample request, collection and processing were informed to and consented by patients, and were carried out in accordance with the Ethics Guidelines and Regulation of the West China Second University Hospital, Sichuan University. Biopsies from 10 patients were analyzed in this study and data

from three cases were presented. All patients were provided with written documents and consented the use of their tissues along with the extraction of their routine histopathological diagnosis for research purpose.

All women were surgically treated at the unit of gynecological surgery at the West China Second University Hospital for different gynecological reasons. Five ovarian tissues diagnosed with ovarian cancer were included in this study along with one 'healthy' ovary without any detectable malignancy. All patients did not receive chemotherapy upon sample collection. Part of the ovarian cortex biopsy was sent for routine pathological investigations, and another part was collected for experiments in this study.

#### Cryosections from biopsies of ovarian cancer

For histological staining, freshly excised tissue blocks were embedded in OCT, followed by snap frozen in liquid nitrogen and stored in  $-80^{\circ}\text{C}$ . Deep frozen tissue blocks were sectioned at  $8\ \mu\text{m}$  using microtome (LEICA, CM3050). For ex vivo culture of ovarian tissue, biopsies were cut into small pieces of  $1\text{--}2\ \text{mm}^3$ , followed by digestion and cell culture procedure as described as above.

#### Irradiation and chemical treatment

Cytotoxic chemical or inhibitors were added to cell culture for indicated period of time for respective assays and at following concentrations: Cisplatin ( $4\ \mu\text{g}/\text{ml}$ ; Supertrack Bio-pharmaceutical, 131,102), MMS ( $0.5\ \text{mg}/\text{ml}$ ); Camptothecin ( $2\ \mu\text{M}$ ; Selleck, S2423), Mitomycin C ( $0.2\ \mu\text{g}/\text{ml}$ ; Selleck, S8146), Paclitaxel ( $35\ \mu\text{M}$ ; Selleck, S1150), Nocodazole ( $100\ \text{ng}/\text{ml}$ ; Sigma, M1404) and hydroxyurea ( $5\ \text{mM}$ ; Selleck, S1896); Caffeine ( $20\ \mu\text{g}/\text{ml}$ ; Sigma, 58-08-2). Ionizing radiation was performed at  $1\ \text{Gray}/\text{min}$  using custom-made X-ray machine (Wandong Ltd., Beijing) and dosages were described in respective experiments.

#### Immunostaining and fluorescence microscopy

Cells grown on cover slips were fixed with 4% paraformaldehyde (PFA), and permeabilized in 0.3% Triton X-100. Cells were blocked at  $37^{\circ}\text{C}$  for 30 min with 3% BSA in PBS supplemented with 3% donkey serum and 0.2% Triton X-100. Fixed cells were then incubated with diluted primary antibodies: Rabbit anti-53BP1 (Cell Signaling, 3428P), Mouse anti- $\gamma\text{H2AX}$  (Millipore, 05-636), Rabbit anti-NBS1-pSerine 343 (Epitomics, 2194-1-1), BRCA1-pS1524 (Bethyl, A300-001A), Mouse anti-TP53-pSerine 15 (Cell Signaling, 2524); Rabbit anti-RPA32-pSerine 33 (NOVUS, NB100-544), Rabbit anti-ssDNA (IBL, 18731). After extensive wash by PBS, coverslips were incubated with secondary antibodies (Rabbit IgG F(ab')<sub>2</sub> fragment-Cy3 and goat anti-Mouse IgG-FITC antibody, Sigma) for 30 min. After mounting with DAPI

solution (VECTOR, H-1200), images were obtained using an Olympus epifluorescent microscope (BX 51) and analyzed with Image-pro plus (Applied Imaging). 100–200 cells or MN from 3 independent experiments were counted for quantitative immunofluorescent assays.

#### Statistical analysis

Statistical analysis was performed with SPSS 20.0 software. All data was from three parallel assays. Student's *t*-test (two-tailed) and one-way ANOVA was the basis of statistical significance calculating and the level of significance was set at  $P < 0.05$ . Correlation was calculated by using Pearson's correlation equations. Microsoft Office Excel 2003 was used for plotting.


## Results

#### Tendency of micronuclei formation in ovarian cancer cells

To characterize micronuclei formation in ovarian cancer cells, we induced DSBs by ionizing irradiation (IR) in an OC cell line (OVCAR-8). One hour after IR treatment, plenty of  $\gamma\text{H2AX}$  and 53BP1 ionizing radiation-induced foci (IRIF) representing DSBs emerged (fig. 1a).  $\gamma\text{H2AX}$  is recruited to DSB after IR exposure and decline when damages are eliminated (fig. 1b). Twelve hours later, while  $\gamma\text{H2AX}$  IRIF diminished, increment of micronuclei was observed, showing a dosage-dependent effect (fig. 1c). In these IR-induced micronuclei compartments, a significant fraction contained DSBs marked by  $\gamma\text{H2AX}$  foci, consistent to previous works reports showing that micronuclei contains broken chromosomes expel from main nuclei [16, 22] (fig. 1d). The micronuclei induction is due to the generation of DSBs as enumeration of IR-induced MN at 12 h post-IR was well correlated with the number of  $\gamma\text{H2AX}$  IRIF immediately after irradiation (fig. 1e). To evaluate the MN induction by different genotoxic reagents, OVCAR-8 cells were subjected to treatments of replication inhibitor (Hydroxyurea/HU, Caffeine), clastogens (Camptothecin/CPT, Mitomycin C/MMC, Methyl methanesulfonate/MMS, Cisplatin), UV radiation mimic (4-NQO) and radiation (Ultraviolet/UV and IR) (fig. 1f). Strikingly, although all reagents but UV induced MN at different levels, IR treatment displayed the greatest potential to induce micronuclei compared with other mutagens. Thus, OVCAR-8 cells are inclined to micronuclei formation after genotoxic challenges, especially upon DSB generation.

#### Abnormal mitosis associated with increment of micronuclei

Abnormal mitosis emerges in OVCAR-8 cells after radiation exposure, occurring as lagging chromosomes, chromosomal bridges or severed DNA fragments (fig. 2a). Prevalent aberrant mitosis were detected in irradiated OVCAR-8 cells as visualized by DAPI (4',6-diamidino-2-phenylindole) staining, with 79.3% and 90% after 2 Gy and




5 Gy radiation in comparison with untreated (9.6%, fig. 2b), reminiscent of the elevated level of MN with increased IR dosage (fig. 1c). These abnormal mitoses were frequently associated with damaged DNA as  $\gamma$ H2AX IRIF on condensed telophase chromosomes was observed in lagging chromosomes, chromosomal bridges, and in extruded post-mitotic micronuclei (fig. 2c), indicating that chromosomes containing unrepaired DSBs accompany the entry of mitosis and are liable to form off-nuclei MN in the coming interphase.

We monitored the correlation of MN formation and mitotic index (MI) in OVCAR-8 and another OC cell line (SKOV-3) in a longer time span of cell cycle after IR treatment. MI of OVCAR-8 cells culminated at 24-h after irradiation (14%) and declined till 36 h post-IR (fig. 2d). Strikingly, micronuclei emerged in these cells followed the wave of mitosis, peaked at 36 h and lagged of MI climax for about 12 h. Similarly, the association of mitosis and micronuclei induction was reproduced in a second ovarian cancer cells (SKOV-3), though the induction of micronuclei is less pronounced than OVCAR-8 (fig. 2e). Therefore, frequent chromosomal aberrance and passage of unrepaired DSBs through

mitosis contribute to the formation of micronuclei in ovarian cancer cells.

#### Evolution of cytoplasmic micronuclei

Micronuclei are still active in DNA metabolism UV reflecting in their dynamic morphology [23]. We firstly used DAPI staining to visualize micronuclei at different time points. Apparently, most micronuclei detected within 12 h were small and compact, easily staining and captured by DAPI staining (fig. 3a). In contrast, a significant proportion of micronuclei in later post-IR windows (36 h) displayed larger volume and more resistant to DAPI staining. Accordingly, we categorize micronuclei into three stages: early-phase of compact with DAPI staining, late-phase of enlarged volume but visible DAPI signals, and very late phase MN with very weak DAPI signals that can only be captured by imaging enhancement (fig. 3a). The proportions of MN at different stages changed after IR: the late and very late stages accounted for 17.7% of total MN before IR treatment while increased to 63% at 48 h post-IR (fig. 3b). Thus, dynamic changes of morphology in micronuclei reflect a gradual evolution of MN with correlated changed of DNA status.



### DSB recruitment of signaling factors in micronuclei is different from nuclear DDR


The off-nuclei micronuclei compartments still contain the nucleoplasmic components that are necessary for DNA metabolism. Enclosed repair factors, like  $\gamma$ H2AX and 53BP1, are liable to be attracted to DNA breaks in post-mitotic micronuclei. We monitored the activation of these DSB factors in different MN compartments. As shown in Fig. 3c,  $\gamma$ H2AX was predominantly positive in early micronuclei (53.5%) while diminished in late-stage compartments (14.2%). On the contrary, 53BP1 displayed opposite distribution pattern as early-stage micronuclei hardly contained 53BP1 foci but exhibited a dramatic enrichment in late stages (3.4% versus 53.9%) (figs. 3d and e). Lack of 53BP1 in early MN could be explained by the exclusion of 53BP1 from the mitotic DSBs where  $\gamma$ H2AX loading were well preserved (fig. 3f). This mechanism results in immediate appearance of  $\gamma$ H2AX IRIF in post-mitotic MN, whereas 53BP1 only aggregates to DSBs in late-stage compartments. As such, in contrast to the DSB loading of repair factors in main nuclei bodies, co-localization of  $\gamma$ H2AX and 53BP1 foci in IR-induced micronuclei compartments was rare (Nuclear compartments: 92.5%, MN compartments: 13.2%;

fig. 3g). Thus, although nuclear repair factors participate in DDR in micronuclei, the signaling mechanisms are different between these separated compartments.

Moreover, we noticed the differential DSB-recruitment of  $\gamma$ H2AX and 53BP1 in spontaneous (without irradiation) and DSB-induced MN. The number of  $\gamma$ H2AX was comparable (53.5% and 67.7% in spontaneous and post-IR MN, respectively), whereas spontaneous MN containing 53BP1 foci was rare, in sharp contrast to the substantial accumulation of 53BP1 foci in IR-induced compartments (5.7% versus 57.3%, fig. 3h). This lack of 53BP1 foci in spontaneous MN may reflect its origin from replication stress, where accumulation of ssDNA instead of DSBs promotes the phosphorylation of H2AX but excludes loading of 53BP1. Thus, spontaneous micronuclei in OVCAR-8 cells are mainly stemmed from chromosomal fragments containing replication damages whose damage signaling is distinct from DSB-induced MN.

### Extensive DNA end processing in late-stage micronuclei

The changes of DAPI staining in early and late stage MN suggest alteration of DNA status: while DAPI fluorescent dye binds to the major grooves of intact double




strand DNA instead of modified DNA structure like single stranded DNA (ssDNA) resected from DSB ends, the attenuated affinity of DAPI for DNA content in late-stage MN suggests collapse of double strand DNA, possibly caused by nucleases that process broken DNA ends. We were prompted to examine the activity of DNA end resection that may cause the disappearance of DAPI signals in late stages of micronuclei. We visualized ssDNA by immunostaining with antibodies specific to ssDNA and phosphorylated replication protein A (RPA32) that coats the ssDNA filaments [24]. Micronuclei displayed a significant increase of RPA32 phosphorylation at 36 h after IR in comparison to untreated cells (44.7% vs. 11.7%), and so as to the ssDNA signal per se (36.7% vs. 18.3%, fig. 4a). Moreover, generation of ssDNA accompanied with the activation of repair factors indicated by the phosphorylation of NBS1, BRCA1 and TP53 (Fig. 4b). Conspicuously, all of these DDR factors were mainly detected in late-phase MN with weak DAPI staining, while the corresponding signals have diminished in main nuclear compartments (fig. 4a and b), indicating slow ssDNA processing kinetics in MN. Intriguingly, although knocking down of a set of ssDNA

processing factors including BRCA1, MRE11 and WDR70 (an epigenetic regulator for long-range resection) [25, 26] dramatically inhibited the formation of IR-induced RPA foci in main nuclei, RPA32 phosphorylation in MN was only marginally affected (fig. 4c), indicating ssDNA processing is not synchronized between MN and nuclei and likely involved in distinct resection factors. Thus, we conclude that DNA lesions in MN are subjected to structural processing that generates a significant amount of ssDNA via partially overlapped mechanism of nuclei.

#### Micronuclei formation in ovarian cancer


Apart from characterization of micronuclei formation in cell lines of ovarian cancer, we also monitored MN in biopsies of human ovarian cancer. Due to the compact volume of the cancerous cells and weak DAPI staining of micronuclei, we monitored DDR protein markers in off-nuclear compartments in tissues from clinical derived biopsies. In primary cultures of these tumor tissues, we visualized MN-like compartments by detecting cytoplasmic 53BP1 and  $\gamma$ H2AX (fig. 5a and b). Clearly, large proportion of primary OC cells contained



**Fig. 4** Active DNA end processing in late micronuclei compartments. **a**: Detection and quantification of RPA32 phosphorylation (pSerine 33) and ssDNA by specific antibodies in MN compartments of OVCAR-8 cells 36 h after 2-Gy irradiation. Note the nuclear signals have reduced while those in MN were intense.  $n = 3$  biological repeats. Error bars = s.d.  $**P < 0.01$ ;  $***P < 0.005$  ( $t$ -test). **b**: Immunostaining and enumeration of phosphorylated NBS1-pSerine 343, BRCA1-pSerine 1524 and TP53-pSerine 15 in MN compartments.  $**P < 0.01$ ;  $***P < 0.005$  ( $t$ -test). **c**: Representative images (Upper panel) and quantification of RPA signal in MN compartments (Lower left) or RPA foci in nuclei (lower right) of post-IR OVCAR-8 cells after indicated treatments. Pro-resection genes (MRE11, BRCA1 and WDR70) were knockdown by specific siRNA. Percentage of positive RPA32-pS33 MN population was calculated after 36 h of IR treatment

off-nuclear compartments with activated DDR signals. Mirroring the weak DAPI staining in late-stage MN of OVCAR-8 cells, many of the MN-like compartments in primary OC culture displayed invisible DAPI signal but easily detected  $\gamma$ H2AX/53BP1, suggesting that DNA fragments was undergoing extensive structural changes. Moreover, similar to the sample of borderline stage (OC20, fig. 5a), immunostaining for phosphorylated TP53

in cryosections showed frequent spontaneous MN-like structures with positive pSerine15 in high-grade serous ovarian cancer samples (fig. 5c), indicating frequent emergence of MN during cancer development. Therefore, ovarian cancers from borderline to advanced stages are prone to develop micronuclei containing processed DNA structures that are potentially toxic to nuclear genomes.



## Discussion

DNA damage responses play important roles in maintaining genome stability. Unrepaired DNA lesions are transmitted to daughter cells, causing elevated levels of mutations, chromosomal aberration or tumor predisposition. Micronuclei are resulted from broken chromosomes, especially after chemo- or radio-therapies. Although the formation of micronuclei is traditionally considered as marker for genome instability, recent advances of genomic sequencing and the development of high-resolution microscopy have built up a more refined scenario of DNA damage and micronuclei [21]. DNA fragments in micronuclei is under replicated, insufficiently repaired, and when they are re-incorporated in the daughter nuclei, they contribute to genomic instability such as chromothripsis, a massive, complex and focal rearrangement restricted to only one or few chromosomes. Generation of micronuclei and ensuing massive rearrangement offers even better chance than point mutation for post-therapy cancer cells with respect of genomic variation and acquirement of potential of resistance and recurrence.

Previous in vitro MN assay showed two population of micronuclei: those with less than 1/4 the diameter of the main nuclei (Type I) and others with 1/4–1/2 of the size (Type II) [18]. Here we show that 53BP1 and  $\gamma$ H2AX

shown by immunostaining display strong co-localization in nuclei compartments but are segregated in MN, reflecting distinct kinetics and mechanism of DNA metabolism between the two compartments. Also, accumulation of ssDNA and RPA in late-stage MN is accordance to the disappearance of  $\gamma$ H2AX foci and extensive processing of DSB ends indicated by diminished DAPI signals. Accordingly, micronuclei can be classified into two metabolism-related stages: early-stage compartments characterized with  $\text{DAPI}^{\text{strong}} \gamma\text{H2AX}^+ 53\text{BP1}^- \text{ssDNA}^-$  signals and compact size correspond to Type I MN; and those in late stages with  $\text{DAPI}^{\text{weak}} \gamma\text{H2AX}^- 53\text{BP1}^+ \text{ssDNA}^+$  are related to large volume Type II MN compartments. The early-stage MN represent those of recent mitotic exist, without extensive DNA end processing, whereas the late-stage counterparts contain extensively processed ssDNA.

It was proposed that DDR signaling activated by DSBs is incomplete in mitosis [27]. Thus, while signaling factors like  $\gamma$ H2AX is recruited to damaged mitotic chromatin, other factors (53BP1) will be loaded after mitosis when the micronuclei have formed. In this regard, our observation of low ratio of overlapping  $\gamma$ H2AX/53BP1 signal in micronuclei is consistent to previous report showing that not all MN display full co-localization between  $\gamma$ H2AX and MRE11 or 53BP1 [28].



Although other reports explained that this lack of co-localization caused by cell cycle-specific recruitment of DDR factors and by nucleocytoplasmic transport defects of MN, our data also suggest the exclusion of  $\gamma$ H2AX in late-stage MN might be caused by extensive processing of DNA.

To generate long stretches of ssDNA required for HR repair in nuclei, a series of nucleolytic enzymes are recruited to the DSBs. MRN and CTIP mediate the short-range resection while BLM-DNA2 carry out the long-range resection to produce functional RPA-coated ssDNA filaments. BRCA1 and 53BP1, as well as epigenetic factors like WDR70 that regulates the accessibility of repair factors in the vicinity of DSBs, constitute a tightly controlled resection promoter that determine the efficacy and extension of resection nucleases [13, 25]. However, in the case of dicentric chromosome formed after telomere crisis, chromothripsis and kataegis requires cytoplasmic 3'-nuclease TREX1 to generate RPA-coated ssDNA and resolve chromatin bridges [29]. This could be the case for micronuclei with membrane rupture that allows the access of cytoplasmic TREX1 to DNA fragments and generate ssDNA in MN. Thus, the TREX1-dependent 3'-nuclease activity may be a substitute mechanism for MRN-, BRCA1- and WDR70-independent resection in micronuclei.

The main obstacle for ovarian cancer therapy is the high incidence of recurrence and resistance. The first-line anti-OC therapy targeting DNA metabolism and chromosomal stability (Cisplatin and Taxol) cause genomic rearrangement and other mutagenic events, which are thought to be associated with quick development of drug resistance. Not until recent time, micronuclei is regarded as the results of the above genome instability mechanisms, but not the potent driving force of next round of genomic rearrangement. Because micronuclei can exist for 1–4 mitoses and the fates varies from exclusion from cells, reintegration into main nucleus, or being digested in situ [30], they can in turn trigger devastating genomic variation in next round of mitosis or upon spillage of MN contents (like ssDNA or other toxic structures). In accordance to this hypothesis, recent studies suggest that DSB-induced micronuclei cause large-scale genomic rearrangement including chromothripsis or chromosomal shattering, potentially contributes to quick changes of genomic variation in somatic genomes of tumor [31–33]. As such, the micronuclei-associated genomic evolution may provide alternative explanations to the resistance encountered in anti-tumor therapy. Indeed, our work strongly suggest that the presence of bulky amount of ssDNA in micronuclei can be potential substrates employed by illegitimate homologous recombination repair upon reintegrating into the nuclei compartments, causing catastrophic and localized rearrangement.

## Conclusions

Thus, our findings show the liability of MN-associated DNA to be processed into abnormal structures in ovarian cancer cells and offer a novel mechanism for the MN-driven genomic adaptation that eventually leads to drug resistance and recurrence.

## Abbreviations

CPT: Camptothecin; DAPI: 4',6-diamidino-2-phenylindole; DDR: DNA damage responses; DSB: Double strand break; IR: Ionizing radiation; IRIF: Ionizing radiation-induced foci; MN: micronuclei; RPA: Replication protein A; ssDNA: Single-strand DNA

## Funding

This work is supported by the Ministry of Science and Technology of China (2013CB911000), NSF China (31171319 and 31471276), Department of Science and Technology of Sichuan Province (2014KJT060-2014SZ and 2017FZ0034).

## Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

## Authors' contributions

JY, XW and JW performed cellular and imaging assays. ZT and LG analysed biopsies. MZ1, AW carried out proliferation and inhibitor assays. MZ and DL advised on the clinical investigation. CL and JC directed the project. ZT and CL summarized the data and wrote the manuscript. All authors have read and approved the manuscript.

## Ethics approval and consent to participate

All performance of sample request, collection and processing were informed and consented by patients in written forms, and were carried out in accordance with the Ethics Guidelines and Regulation of the West China Second University Hospital, Sichuan University. This study was approved by the Ethics Committee of the University Hospital.

## Competing interests

The authors declare that they have no competing interests in the manuscript.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Author details

<sup>1</sup>Department of Pharmacology, West China Second University Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Ministry of Education), Sichuan University, Chengdu 610041, People's Republic of China. <sup>2</sup>Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu 610041, People's Republic of China. <sup>3</sup>Department of Laboratory Medicine, Suining Central Hospital, 629000 Suining, People's Republic of China. <sup>4</sup>College of Pharmacy, Southwest Minzu University, No.16 South Section 4, Yihuan Road, Chengdu 610041, People's Republic of China.

Received: 21 August 2017 Accepted: 8 April 2018

Published online: 16 April 2018

## References

- DM P, Bray F, Ferlay J. Global cancer statistics [J]. *CA Cancer J Clin*. 2005; 55(2):74–108.
- Venkitaraman AR. Cancer Suppression by the Chromosome Custodians, BRCA1 and BRCA2. *Science*. 2014;343(6178):1470–5.
- Wang YK, et al. Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. *Nat Genet*. 2017;49(6):856.
- Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. *Nat Rev Cancer*. 2010;10(11):803–8.
- Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. *Mol Oncol*. 2014;8(6):1095–111.

6. Salomon-Perzynski A, et al. High-grade serous ovarian cancer: the clone wars. *Arch Gynecol Obstet*. 2017;295(3):569–76.
7. Cooke SL, Brenton JD. Evolution of platinum resistance in high-grade serous ovarian cancer. *Lancet Oncol*. 2011;12(12):1169.
8. Edwards SL, et al. Resistance to therapy caused by intragenic deletion in BRCA2. *Nature*. 2008;451(7182):1111.
9. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. *Nature*. 2009;461:1071–8.
10. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. *Nature*. 2004;432:316–23.
11. Rogakou EP, et al. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. *J Biol Chem*. 1998;273(10):5858–68.
12. Olive PL. Retention of cH2AX foci as an indication of lethal DNA damage. *Radiother Oncol*. 2011;101:18–23.
13. Bunting SF, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. *Cell*. 2010;141(2):243–54.
14. San Filippo J. P. Sung, and H. Klein, *Mechanism of eukaryotic homologous recombination*. *Annu Rev Biochem*. 2008;77:229–57.
15. Gisselsson D, et al. Abnormal nuclear shape in solid tumors reflects mitotic instability. *Am J Pathol*. 2001;158(1):199.
16. Medvedeva NG, et al. Phosphorylation of histone H2AX in radiation-induced micronuclei. *Radiat Res*. 2007;68(4):493–8.
17. Muller WU, et al. Micronuclei: a biological indicator of radiation damage. *Mutat Res*. 1996;366(2):163–9.
18. Hashimoto K, et al. An in vitro micronucleus assay with size-classified micronucleus counting to discriminate aneugens from clastogens. *Toxicol in Vitro*. 2010;24(1):208–16.
19. Liu ZZ, et al. Prediction value of radiosensitivity of hepatocarcinoma cells for apoptosis and micronucleus assay. *World J Gastroenterol*. 2005;11(44):7036–9.
20. Widel M, et al. The increment of micronucleus frequency in cervical carcinoma during irradiation in vivo and its prognostic value for tumour radiocurability. *Br J Cancer*. 1999;80(10):1599–607.
21. Terradas M, Martín M, Genescà A. Impaired nuclear functions in micronuclei results in genome instability and chromothripsis. *Arch Toxicol*. 2016;90(11):2657–67.
22. Terradas M, et al. DNA lesions sequestered in micronuclei induce a local defective-damage response. *DNA Repair (Amst)*. 2009;8(10):1225–34.
23. Haaf T, et al. Sequestration of mammalian Rad51-recombination protein into micronuclei. *J Cell Biol*. 1999;144(1):11–20.
24. Bochkareva E, et al. The RPA32 subunit of human replication protein a contains a single-stranded DNA-binding domain. *J Biol Chem*. 1998;273(7):3932–6.
25. Zeng M. CRL4Wdr70 regulates H2B monoubiquitination and facilitates Exo1-dependent resection. *Nat Commun*. 2016;7:11364.
26. Chen L, et al. Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair. *J Biol Chem*. 2008;283(12):7713–20.
27. Giunta S, Jackson SP. Give me a break, but not in mitosis: the mitotic DNA damage response marks DNA double-strand breaks with early signaling events. *Cell Cycle*. 2011;10(8):1215–21.
28. Terradas M, et al. DNA lesions sequestered in micronuclei induce a local defective-damage response. *DNA Repair*. 2009;8(10):1225–34.
29. Maciejowski J, et al. Chromothripsis and Kataegis induced by telomere crisis. *Cell*. 2015;163(7):1641–54.
30. Huang Y, et al. The fate of micronucleated cells post X-irradiation detected by live cell imaging. *DNA Repair*. 2011;10(6):629.
31. Storchová Z, Kloosterman WP. The genomic characteristics and cellular origin of chromothripsis. *Curr Opin Cell Biol*. 2016;40:106–13.
32. Crasta K, et al. DNA breaks and chromosome pulverization from errors in mitosis. *Nature*. 2012;482(7383):53–8.
33. Ly P, et al. Selective Y centromere inactivation triggers chromosome shattering in micronuclei and repair by non-homologous end joining. *Nat Cell Biol*. 2017;19(1):68–75.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

